Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
CymaBay Therapeutics, Inc. (0001042074)
Standardized SEC financial data for CymaBay Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001042074 · Pharmaceutical Preparations.
Income statement
USD
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
Revenue
—
—
—
$0
$0
$31.1M
R&D expense
$58.1M
$83.8M
$35.9M
$64.5M
$68.0M
$80.8M
SG&A expense
$14.4M
$19.2M
$16.7M
$23.0M
$25.1M
$52.0M
Operating income
-$72.5M
-$108.2M
-$52.6M
-$87.6M
-$93.1M
-$101.7M
EBITDA
-$72.4M
-$107.6M
-$52.0M
-$86.9M
-$92.5M
-$101.0M
Interest expense
$336K
—
—
$2.6M
$14.9M
$18.9M
Income tax
$0
$0
$0
$0
$0
$0
Net income
-$73.0M
-$102.8M
-$51.0M
-$90.0M
-$106.0M
-$105.4M
EPS (diluted)
$-1.26
$-1.53
—
$-1.27
$-1.21
$-0.99
Standardized from CymaBay Therapeutics, Inc.'s SEC filings — per-share figures split-adjusted. Full history via the API.